Kimmo Kettunen

Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study (2024)

EBioMedicine

Kettunen, Kimmo; Mathlin, Julia; Lamminen, Tarja; Laiho, Asta; Häkkinen, R. Merja; Auriola, Seppo; Elo, L. Laura; Boström, J. Peter; Poutanen, Matti; Taimen, Pekka

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type? (2020)

European Urology

Kimmo Kettunen, Peter Boström, Pekka Taimen

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells (2019)

European Urology

Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, Taija Heinosalo, Gun West , Irena Saarinen, Katja Kaipio, Juha Rantala, Chris Albanese, Matti Poutanen, Pekka Taimen

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4 (2019)

European Urology

Kimmo Kettunen, Peter J. Boström, Pekka Taimen

(O2 Muu julkaisu )

Contact

Links

Publications

Sort by:

Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study (2024)

Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells (2019)

Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Bostrom, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4 (2019)